LncRNA RMRP silence curbs neonatal neuroblastoma progression by regulating microRNA-206/tachykinin-1 receptor axis via inactivating extracellular signal-regulated kinases

References

• Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014;64:83–103. doi:10.3322/caac.21219.
   PubMed Web of Science ®Google Scholar
• Irwin MS, Park JR. Neuroblastoma: paradigm for precision medicine. Pediatr Clin North Am. 2015;62:225–256. doi:10.1016/j.pcl.2014.09.01.
   PubMed Web of Science ®Google Scholar
• Fisher JP, Tweddle DA. Neonatal neuroblastoma. Semin Fetal Neonatal Med. 2012;17:207–215. doi:10.1016/j.siny.2012.0.002.
   PubMed Web of Science ®Google Scholar
• Interiano RB, Davidoff AM. Current management of neonatal neuroblastoma. Curr Pediatr Rev. 2015;11:179–187.
   PubMed Web of Science ®Google Scholar
• Huarte M. The emerging role of lncRNAs in cancer. Nat Med. 2015;21:1253–1261. doi:10.1038/nm.3981.
   PubMed Web of Science ®Google Scholar
• Pandey GK, Kanduri C. Long noncoding RNAs and neuroblastoma. Oncotarget. 2015;6:18265–18275. doi:10.18632/oncotarget.421.
   PubMedGoogle Scholar
• Pandey GK, Mitra S, Subhash S, Hertwig F, Kanduri M, Mishra K, Fransson S, Ganeshram A, Mondal T, Bandaru S, et al. The risk-associated long noncoding RNA NBAT-1 controls neuroblastoma progression by regulating cell proliferation and neuronal differentiation. Cancer Cell. 2014;26:722–737. doi:10.1016/j.ccell.2014.09.014.
   PubMed Web of Science ®Google Scholar
• Hermanns P, Reicherter K, Lee B. RMRP (RNA component of mitochondrial RNA processing endoribonuclease). Atlas Genetics Cytogenetics Oncol Haematol. 2008;12.
   Google Scholar
• Meng Q, Ren M, Li Y, Song X. LncRNA-RMRP acts as an oncogene in lung cancer. PLoS ONE. 2016;11:e0164845. doi:10.1371/journal.pone.016484.
   PubMed Web of Science ®Google Scholar
• Shao Y, Ye M, Li Q, Sun W, Ye G, Zhang X, Yang Y, Xiao B, Guo J. LncRNA-RMRP promotes carcinogenesis by acting as a miR-206 sponge and is used as a novel biomarker for gastric cancer. Oncotarget. 2016;7:37812–37824. doi:10.18632/oncotarget.9336.
   PubMedGoogle Scholar
• Feng W, Li L, Xu X, Jiao Y, Du W. Up-regulation of the long non-coding RNA RMRP contributes to glioma progression and promotes glioma cell proliferation and invasion. Arch Med Sci. 2017;13:1315–1321. doi:10.114/aoms.2017.66747.
   PubMed Web of Science ®Google Scholar
• Wang R, Hu Y, Song G, Hao CJ, Cui Y, Xia HF, Ma X. MiR-206 regulates neural cells proliferation and apoptosis via Otx2. Cell Physiol Biochem. 2012;29:381–390. doi:10.119/000338493.
   Google Scholar
• Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell. 2011;146:353–358. doi:10.1016/j.cell.2011.07.014.
   PubMed Web of Science ®Google Scholar
• Munoz M, Covenas R. Neurokinin-1 receptor: a new promising target in the treatment of cancer. Discov Med. 10;2010:305–313.
   PubMed Web of Science ®Google Scholar
• Munoz M, Covenas R. Involvement of substance P and the NK-1 receptor in cancer progression. Peptides. 2013;48:1–9. doi:10.1016/j.peptides.2013.07.024.
   PubMed Web of Science ®Google Scholar
• Munoz M, Rosso M, Covenas R. The NK-1 receptor: a new target in cancer therapy. Curr Drug Targets. 12;2011:909–921.
   PubMed Web of Science ®Google Scholar
• Mou L, Kang Y, Zhou Y, Zeng Q, Song H, Wang R. Neurokinin-1 receptor directly mediates glioma cell migration by up-regulation of matrix metalloproteinase-2 (MMP-2) and membrane type 1-matrix metalloproteinase (MT1-MMP). J Biol Chem. 2013;288:306–318. doi:10.1074/jbc.M112.389783.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li X, Li J, Hu H, Miao X, Song X, Yang W, Zeng Q, Mou L, Wang R. Human hemokinin-1 promotes migration of melanoma cells and increases MMP-2 and MT1-MMP expression by activating tumor cell NK1 receptors. Peptides. 2016;83:8–15. doi:10.1016/j.peptides.2016.07.004.
   PubMed Web of Science ®Google Scholar
• Novak J, Kruzliak P, Bienertova-Vasku J, Slaby O, Novak M. MicroRNA-206: a promising theranostic marker. Theranostics. 2014;4:119–133. doi:10.710/thno.72.
   PubMed Web of Science ®Google Scholar
• Xiao H, Xiao W, Cao J, Li H, Guan W, Guo X, Chen K, Zheng T, Ye Z, Wang J, et al. miR-206 functions as a novel cell cycle regulator and tumor suppressor in clear-cell renal cell carcinoma. Cancer Lett. 2016;374:107–116. doi:10.1016/j.canlet.2016.01.032.
   PubMed Web of Science ®Google Scholar
• Pan JY, Sun CC, Bi ZY, Chen ZL, Li SJ, Li QQ, Wang YX, Bi YY, Li DJ. miR-206/133b cluster: A weapon against lung cancer? Mol Ther Nucleic Acids. 2017;8:442–449. doi:10.1016/j.omtn.2017.06.002.
   PubMedGoogle Scholar
• Pang C, Huang G, Luo K, Dong Y, He F, Du G, Xiao M, Cai W. miR-206 inhibits the growth of hepatocellular carcinoma cells via targeting CDK9. Cancer Med. 2017;6:2398–2409. doi:10.1002/cam4.1188.
   PubMed Web of Science ®Google Scholar
• Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10:704–714. doi:10.1038/nrg2634.
   PubMed Web of Science ®Google Scholar
• Regoli D, Drapeau G, Dion S, D’Orleans-Juste P. Receptors for substance P and related neurokinins. Pharmacology. 1989;38:1–15. doi:10.1159/000138512.
   PubMed Web of Science ®Google Scholar
• Fong TM, Anderson SA, Yu H, Huang RR, Strader CD. Differential activation of intracellular effector by two isoforms of human neurokinin-1 receptor. Mol Pharmacol. 41;1992:24–30.
   PubMed Web of Science ®Google Scholar
• Steinhoff MS, von Mentzer B, Geppetti P, Pothoulakis C, Bunnett NW. Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease. Physiol Rev. 2014;94:265–301. doi:10.112/physrev.00031.2013.
   PubMed Web of Science ®Google Scholar
• Munoz M, Rosso M, Perez A, Covenas R, Rosso R, Zamarriego C, Piruat JI. The NK1 receptor is involved in the antitumoural action of L-733,060 and in the mitogenic action of substance P on neuroblastoma and glioma cell lines. Neuropeptides. 2005;39:427–432. doi:10.1016/j.npep.200.03.004.
   PubMed Web of Science ®Google Scholar
• Akazawa T, Kwatra SG, Goldsmith LE, Richardson MD, Cox EA, Sampson JH, Kwatra MM. A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas. J Neurochem. 2009;109:1079–1086. doi:10.1111/j.1471-419.2009.06032.x.
   PubMed Web of Science ®Google Scholar
• Munoz M, Perez A, Covenas R, Rosso M, Castro E. Antitumoural action of L-733,060 on neuroblastoma and glioma cell lines. Arch Ital Biol. 142;2004:105–112.
   PubMed Web of Science ®Google Scholar
• Henssen AG, Odersky A, Szymansky A, Seiler M, Althoff K, Beckers A, Speleman F, Schafers S, De Preter K, Astrahanseff K, et al. Targeting tachykinin receptors in neuroblastoma. Oncotarget. 2017;8:430–443. doi:10.18632/oncotarget.13440.
   PubMedGoogle Scholar
• Berger M, Von Schweinitz D. Therapeutic innovations for targeting childhood neuroblastoma: implications of the Neurokinin-1 receptor system. Anticancer Res. 2017;37:5911–5918. doi:10.21873/anticanres.12037.
   PubMed Web of Science ®Google Scholar
• Zheng Z, Yan D, Chen X, Huang H, Chen K, Li G, Zhou L, Zheng D, Tu L, Dong XD. MicroRNA-206: effective inhibition of gastric cancer progression through the c-Met pathway. PLoS ONE. 2015;10:e0128751. doi:10.1371/journal.pone.012871.
   PubMed Web of Science ®Google Scholar
• Williams R, Zou X, Hoyle GW. Tachykinin-1 receptor stimulates proinflammatory gene expression in lung epithelial cells through activation of NF-kappaB via a G(q)-dependent pathway. Am J Physiol Lung Cell Mol Physiol. 2007;292:430–437. doi:10.112/ajplung.0047.200.
   PubMed Web of Science ®Google Scholar